Use SGLT 2 Inhibitors, GLP-1 receptor agonists as first-line treatment for patients with diabetes and CVD: ESC 2019 Update

GLP-1 receptor agonists and gliflozins (SGLT 2 Inhibitors) should be used as first-line treatment for blood sugar control in type 2 diabetes patients with established cardiovascular disease or at high risk of cardiovascular disease, stated the guidelines issued at ESC Congress 2019 recently.

The guideline, on diabetes and cardiovascular disease, is developed by the European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD). The recommendations are published in the European Heart Journal.

“The emphasis of these guidelines is to provide state of the art information on how to prevent and manage the effects of diabetes on the heart and vasculature, with a focus on new data that has emerged since the 2013 document," said Professor Francesco Cosentino, ESC Chairperson of the guidelines Task Force and professor of cardiology at the Karolinska Institute and Karolinska University Hospital in Stockholm, Sweden.

Professor Peter J. Grant, EASD Chairperson of the guidelines Task Force and professor of medicine at the University of Leeds, UK said: “Recent trials have shown the cardiovascular safety and efficacy of SGLT2 inhibitors and GLP-1 receptor agonists for type 2 diabetes. We provide clear recommendations here.”

Our main recommendation in the light of these findings is that GLP-1 receptor agonists and gliflozins should be used as first-line treatment in type 2 diabetes patients with established cardiovascular disease or at high risk of cardiovascular disease,” said Prof Cosentino.

Clinical trials on the cardiovascular safety of medications for type 2 diabetes have led to a paradigm shift in glucose-lowering treatment. Two groups of diabetes drugs – GLP-1 receptor agonists and gliflozins – showed cardiovascular safety and benefit in patients with diabetes who either already had heart disease and/or had multiple risk factors.

Many Other recommendations have also been put forward during the congress. Key Recommendations of the ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD include:

• GLP-1 receptor agonists and gliflozins should be used as first-line treatment in type 2 diabetes patients with established cardiovascular disease or at high risk of cardiovascular disease.


• Moderate alcohol intake should not be promoted as a means to protect against cardiovascular disease.


• Statins are not recommended in diabetic women of childbearing potential and should be used with caution in young people.


• Drugs that prevent blood clots – non-vitamin K antagonist oral anticoagulants, specifically rivaroxaban – have been reported to benefit peripheral vascular disease and should be considered in combination with aspirin for patients with diabetes who have poor circulation in the legs.


• PCSK9 inhibitors are advised for patients with diabetes at very high risk of cardiovascular disease who do not achieve low-density lipoprotein (LDL) cholesterol goals despite treatment with statins. In these patients, a more ambitious LDL cholesterol target of below 1.4 mmol/L is recommended.

The global prevalence of diabetes continues to increase. It is predicted that more than 600 million individuals will develop type 2 diabetes worldwide by 2045, with around the same number developing pre-diabetes. Estimates state that diabetes affects 10% of populations in previously underdeveloped countries such as China and India, which are now adopting western lifestyles, and 60 million Europeans, of which half are undiagnosed.

“These figures pose serious questions to developing economies, where the very individuals who support economic growth are those most likely to develop type 2 diabetes and to die of premature cardiovascular disease,” states the document.

Healthy behaviours are the mainstay of preventing cardiovascular disease. Lifestyle changes are now advised to avoid or delay the conversion of pre-diabetes states, such as impaired glucose tolerance, to diabetes. Physical activity, for example, delays conversion, improves glycaemic control and reduces cardiovascular complications.

The document states that moderate alcohol intake should not be promoted as a means to protect against cardiovascular disease. “There has been a long-standing view that moderate alcohol intake has beneficial effects on the prevalence of the cardiovascular disease,” said Prof Grant. “Two high-profile analyses have reported this is not the case and that alcohol consumption does not appear to be beneficial. On the basis of these new findings, we changed our recommendations.”

Self-monitoring of blood glucose and blood pressure is advocated for patients with diabetes to achieve better control. Data has emerged to implicate glucose variability in the causes of heart disease in diabetes. In addition, glucose variation at night is particularly linked with hypoglycaemia and deterioration in the quality of life.

This indicates that it is no longer appropriate to depend on occasional glucose measures to manage control, particularly in type 1 diabetes,” said Prof Cosentino. “At the same time, flash technology has been developed which uses a small sensor worn on the skin to continuously monitor glucose levels. Similar arguments pertain to home blood pressure monitoring.”

Statins are not recommended in diabetic women of childbearing potential and should be used with caution in young people. “We have no experience of the effects of 50 or 60 years of statin use in an individual and we do not advocate non-essential drugs in pregnancy when the potential adverse effects on the unborn child are unknown,” explained Prof Grant.

Drugs that prevent blood clots – non-vitamin K antagonist oral anticoagulants, specifically rivaroxaban – have been reported to benefit peripheral vascular disease and should be considered in combination with aspirin for patients with diabetes who have poor circulation in the legs.

PCSK9 inhibitors are advised for patients with diabetes at very high risk of cardiovascular disease who do not achieve low-density lipoprotein (LDL) cholesterol goals despite treatment with statins. In these patients, a more ambitious LDL cholesterol target of below 1.4 mmol/L is recommended.

Lifestyle advise for patients with diabetes and pre-diabetes

• Avoid alcohol.


• Quit smoking.


• Do moderate-to-vigorous physical activity (a combination of aerobic and resistance exercise) at least 150 minutes per week to prevent/control diabetes – unless contraindicated, such as in patients with severe comorbidities or limited life expectancy.


• Adopt a Mediterranean diet supplemented with olive oil and/or nuts to lower the risk of cardiovascular events.


• Reduce calorie intake to lower excessive body weight.